PMID- 25835132
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150403
LR  - 20200930
IS  - 0974-7796 (Print)
IS  - 0974-7834 (Electronic)
IS  - 0974-7796 (Linking)
VI  - 7
IP  - 2
DP  - 2015 Apr-Jun
TI  - A randomized, double-blind, placebo-controlled, crossover trial of "on-demand" 
      tramadol for treatment of premature ejaculation.
PG  - 205-10
LID - 10.4103/0974-7796.150481 [doi]
AB  - OBJECTIVES: The objective of this study is to assess the dose-related effects of 
      tramadol on a group of patients with premature ejaculation (PE). SUBJECTS AND 
      METHODS: During the period of months between June 2010 and July 2012, 180 PE 
      patients presented to outpatient clinic of our hospital. Patients were randomized 
      in a 1:1:1 fashion to receive different sequences of the three medications: 
      placebo, 50 mg of tramadol and 100 mg of tramadol. Every patient received 10 
      doses of each medication for 2 months. Intra-vaginal ejaculatory latency time 
      (IELT) was recorded in seconds initially and for each arm. Successful treatment 
      of PE is defined if IELT exceeded 120 s. Side-effects of medications were 
      reported. RESULTS: Of patients enrolled, 125 (69.4%) continued the study. 
      Patients' age range was 20-55 years with PE complaint of 1 to 10 years duration. 
      Mean IELT was 72 at presentation, 82 for placebo, 150 for tramadol 50 mg, and 272 
      for tramadol 100 mg (P < 0.001 for all comparisons). PE was successfully treated 
      in only 2.4% of patients with placebo, in contrast to 53.6% and 85.6% with 50 and 
      100 mg tramadol, respectively (P < 0.001 for all comparisons). On multivariate 
      logistic regression analysis, baseline IELT was the only predictor of successful 
      treatment of PE with both tramadol 50 mg (odds ratio [OR]: 1.05, 95% confidence 
      interval [CI]: 1.03-1.07, P < 0.001) and tramadol 100 mg (OR: 1.07, 95% CI: 
      1.04-1.11, P < 0.001). Postmicturition dribble annoyed 12.8% of those who 
      received 50 mg tramadol and 33.6% of those who received 100 mg tramadol (P < 
      0.001). Weak scanty ejaculation was the main complaint in 7.2% versus 21.6% of 
      those using 50 and 100 mg tramadol, respectively (P = 0.002). Two patients 
      discontinued tramadol 100 mg due to side-effects. CONCLUSION: Tramadol 
      hydrochloride exhibits a significant dose-related efficacy and side-effects over 
      placebo for treatment of PE.
FAU - Kurkar, Adel
AU  - Kurkar A
AD  - Department of Urology, Assiut University Hospitals, Assiut 71515, Egypt.
FAU - Elderwy, Ahmad A
AU  - Elderwy AA
AD  - Department of Urology, Assiut University Hospitals, Assiut 71515, Egypt.
FAU - Abulsorour, Sherief
AU  - Abulsorour S
AD  - Department of Urology, Assiut University Hospitals, Assiut 71515, Egypt.
FAU - Awad, Sara M
AU  - Awad SM
AD  - Department of Dermatology and Venorology, Assiut University Hospitals, Assiut 
      71515, Egypt.
FAU - Safwat, Ahmed S
AU  - Safwat AS
AD  - Department of Urology, Assiut University Hospitals, Assiut 71515, Egypt.
FAU - Altaher, Ahmed
AU  - Altaher A
AD  - Department of Urology, Assiut University Hospitals, Assiut 71515, Egypt.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Urol Ann
JT  - Urology annals
JID - 101510823
PMC - PMC4374260
OTO - NOTNLM
OT  - Intra-vaginal ejaculatory latency time
OT  - premature ejaculation
OT  - tramadol hydrochloride
COIS- Conflict of Interest: None.
EDAT- 2015/04/04 06:00
MHDA- 2015/04/04 06:01
PMCR- 2015/04/01
CRDT- 2015/04/04 06:00
PHST- 2014/04/24 00:00 [received]
PHST- 2014/04/27 00:00 [accepted]
PHST- 2015/04/04 06:00 [entrez]
PHST- 2015/04/04 06:00 [pubmed]
PHST- 2015/04/04 06:01 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - UA-7-205 [pii]
AID - 10.4103/0974-7796.150481 [doi]
PST - ppublish
SO  - Urol Ann. 2015 Apr-Jun;7(2):205-10. doi: 10.4103/0974-7796.150481.